Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Akshay Bagai; Deepak L Bhatt; John W Eikelboom; G B John Mancini; Eric A Cohen; Ram Vijayaraghavan; Asim N Cheema; Jacob A Udell; Joel Niznick; Jean-Francois Tanguay; Subodh Verma; Shamir R Mehta

doi:10.1161/CIRCULATIONAHA.115.021158

Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Circulation. 2016 May 24;133(21):2094-8. doi: 10.1161/CIRCULATIONAHA.115.021158.

Affiliations

¹ From Terrence Donnelly Heart Center, St. Michael's Hospital, University of Toronto, ON, Canada (A.B., A.N.C.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.,); Population Health Research Institute, McMaster University and Hamilton Health Sciences, ON, Canada (J.W.E., S.R.M.); Vancouver Hospital, University of British Columbia, Vancouver, Canada (G.B.J.M.); Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (E.A.C.); Division of Cardiology, Rouge Valley Health System, Scarborough, ON, Canada (R.V.); Peter Munk Cardiac Centre, Toronto General Hospital and Women's College Hospital, University of Toronto, ON, Canada (J.A.U.); University of Ottawa, ON, Canada (J.N.); Montreal Heart Institute, Université de Montréal, QC, Canada (J.-F.T.); and Division of Cardiac Surgery, Keenen Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada (S.V.).
² From Terrence Donnelly Heart Center, St. Michael's Hospital, University of Toronto, ON, Canada (A.B., A.N.C.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.,); Population Health Research Institute, McMaster University and Hamilton Health Sciences, ON, Canada (J.W.E., S.R.M.); Vancouver Hospital, University of British Columbia, Vancouver, Canada (G.B.J.M.); Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (E.A.C.); Division of Cardiology, Rouge Valley Health System, Scarborough, ON, Canada (R.V.); Peter Munk Cardiac Centre, Toronto General Hospital and Women's College Hospital, University of Toronto, ON, Canada (J.A.U.); University of Ottawa, ON, Canada (J.N.); Montreal Heart Institute, Université de Montréal, QC, Canada (J.-F.T.); and Division of Cardiac Surgery, Keenen Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada (S.V.). [email protected] [email protected].

PMID: 27217435
DOI: 10.1161/CIRCULATIONAHA.115.021158

No abstract available

Publication types

Case Reports
Review

MeSH terms

Acute Coronary Syndrome / diagnosis
Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / surgery
Aged
Aged, 80 and over
Aspirin / administration & dosage*
Aspirin / adverse effects
Drug Administration Schedule
Female
Hemorrhage / chemically induced
Hemorrhage / diagnosis
Humans
Male
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Precision Medicine / methods*
Purinergic P2Y Receptor Antagonists / administration & dosage*
Purinergic P2Y Receptor Antagonists / adverse effects
Ticlopidine / administration & dosage
Ticlopidine / adverse effects

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Ticlopidine
Aspirin